MétaCan
Menu
Back to cohort
Record W2007928017 · doi:10.1182/blood-2012-02-409763

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

2012· article· en· W2007928017 on OpenAlexaff
Erica D. Warlick, Kwang Woo Ahn, Tanya L. Pedersen, Andrew Artz, M. Lima, Michael A. Pulsipher, Görgün Akpek, Mahmoud Aljurf, Jean‐Yves Cahn, Mitchell S. Cairo, Yi‐Bin Chen, Brenda Cooper, Abhinav Deol, Sergio Giralt, Vikas Gupta, H. Jean Khoury, Holbrook E. Kohrt, Hillard M. Lazarus, Ian A. Lewis, Richard F. Olsson, Joseph Pidala, Bipin N. Savani, Matthew D. Seftel, Gèrard Socié, Martin S. Tallman, Celaettin Ustun, Ravi Vij, Lars L. Vindeløv, Daniel J. Weisdorf

Bibliographic record

VenueBlood · 2012
Typearticle
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsUniversity of ManitobaCancerCare Manitoba
FundersNational Cancer InstituteNational Blood FoundationGenentechAstellas PharmaOffice of Naval ResearchBe The Match FoundationEisaiCellGenixMedical College of WisconsinHistoGeneticsNational Heart, Lung, and Blood InstituteBlue Cross and Blue Shield AssociationNational Institute of Allergy and Infectious DiseasesCelgeneBiogenHealth Resources and Services AdministrationAstellas Pharma USAmgenIC Design Education Center
KeywordsMedicineInternal medicineChronic myelogenous leukemiaImatinibGastroenterologyGraft-versus-host diseaseLeukemiaCohortTyrosine-kinase inhibitorHematopoietic stem cell transplantationTransplantationSurgeryCancerMyeloid leukemia

Abstract

fetched live from OpenAlex

Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.116
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.232
Teacher spread0.223 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations50
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueBloodSame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207